Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Jul 3, 2026·v1

Hyperthermia and radiation versus chemoradiation for cervical cancer

For patients with locally advanced cervical cancer (LACC), adding modulated electro-hyperthermia (mEHT) to standard [[chemoradiotherapy]] (CRT) significantly improves local control compared to CRT alone [1]. This benefit is maintained in HIV-positive populations without increasing treatment-related toxicity or compromising compliance with [[cisplatin]]-based regimens [1]. In a

Moderate Evidence6 references·1,477 words·6 min read·v1
For patients with locally advanced cervical cancer (LACC), adding modulated electro-hyperthermia (mEHT) to standard [[chemoradiotherapy]] (CRT) significantly improves local control compared to CRT alone [1]. This benefit is maintained in HIV-positive populations without increasing treatment-related toxicity or compromising compliance with [[cisplatin]]-based regimens [1].

Board Review — High Yield

  • •Modulated electro-hyperthermia (mEHT) significantly improves local control in locally advanced cervical cancer when added to chemoradiotherapy [1].
  • •Cisplatin-based chemoradiotherapy replaced radiotherapy alone as the standard of care based on five landmark randomized trials.
  • •Modulated electro-hyperthermia (mEHT) significantly improves local control in LACC when added to standard chemoradiotherapy [1].
  • •Tri-modality therapy (CRT + hyperthermia) significantly improves 5-year overall survival compared to CRT alone (HR 0.67).

Deep Dive — Evidence Details

References

  1. [1]

    Minnaar CA, Kotzen JA, Naidoo T et al.. “Analysis of the effects of mEHT on the treatment-related toxicity and quality of life of HIV-positive cervical cancer patients.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2020). PMID: 32180481 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  2. [2]

    Jones EL, Samulski TV, Dewhirst MW et al.. “A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.” Cancer (2003). PMID: 12872345 ↗

    L2TRIAL_NONRANDOMCited in: Background: Evolution of Treatment
  3. [3]

    Harima Y, Ohguri T, Imada H et al.. “A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2016). PMID: 27418208 ↗

    L1RCTCited in: Applicability and Caveats
  4. [4]

    Ohguri T, Harima Y, Imada H et al.. “Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2017). PMID: 28679349 ↗

    L1RCTCited in: Applicability and Caveats
  5. [5]

    Minnaar CA, Kotzen JA, Ayeni OA et al.. “The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial.” PloS one (2019). PMID: 31216321 ↗

    L1RCTCited in: Applicability and Caveats
  6. [6]

    Yea JW, Park JW, Oh SA et al.. “Chemoradiotherapy with hyperthermia versus chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2021). PMID: 34477028 ↗

    L2SR_OBSCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…